Complete financial analysis of Revvity, Inc. (RVTY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revvity, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- GuestLogix Inc. (GUESF) Income Statement Analysis – Financial Results
- GMI Technology Inc. (3312.TW) Income Statement Analysis – Financial Results
- Grasim Industries Limited (GRASIM.BO) Income Statement Analysis – Financial Results
- EQT AB (publ) (EQT.ST) Income Statement Analysis – Financial Results
- SDC TECHMEDIA LIMITED (SDC.BO) Income Statement Analysis – Financial Results
Revvity, Inc. (RVTY)
About Revvity, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.75B | 3.31B | 5.07B | 3.78B | 2.88B | 2.78B | 2.26B | 2.12B | 2.26B | 2.24B | 2.17B | 2.12B | 1.92B | 1.70B | 1.81B | 1.94B | 1.79B | 1.55B | 1.47B | 1.69B | 1.54B | 1.50B | 1.33B | 1.70B | 1.36B | 1.41B | 1.46B | 1.43B | 1.42B | 1.33B | 2.70B | 2.79B | 2.69B | 2.47B | 1.65B | 1.41B | 1.24B | 1.15B | 1.16B |
| Cost of Revenue | 1.21B | 1.32B | 2.22B | 1.67B | 1.49B | 1.44B | 1.18B | 1.10B | 1.24B | 1.23B | 1.19B | 1.15B | 1.07B | 945.72M | 1.03B | 1.11B | 1.06B | 918.29M | 859.30M | 1.01B | 906.27M | 904.10M | 721.73M | 918.43M | 787.30M | 991.30M | 1.04B | 1.01B | 1.01B | 957.80M | 2.30B | 2.39B | 2.31B | 2.14B | 1.35B | 1.11B | 984.00M | 935.30M | 927.90M |
| Gross Profit | 1.54B | 1.99B | 2.85B | 2.11B | 1.40B | 1.34B | 1.07B | 1.01B | 1.02B | 1.00B | 976.97M | 963.21M | 850.58M | 758.63M | 779.79M | 830.11M | 724.74M | 628.07M | 614.54M | 680.55M | 628.95M | 600.88M | 608.33M | 776.84M | 575.80M | 416.60M | 420.70M | 419.50M | 407.00M | 374.80M | 393.20M | 401.50M | 382.00M | 333.50M | 303.80M | 292.00M | 251.90M | 209.80M | 227.20M |
| Gross Profit Ratio | 55.98% | 60.08% | 56.27% | 55.78% | 48.41% | 48.27% | 47.54% | 47.90% | 45.28% | 44.90% | 45.10% | 45.54% | 44.27% | 44.51% | 43.03% | 42.84% | 40.55% | 40.62% | 41.70% | 40.34% | 40.97% | 39.93% | 45.74% | 45.82% | 42.24% | 29.59% | 28.80% | 29.39% | 28.67% | 28.13% | 14.57% | 14.40% | 14.21% | 13.48% | 18.41% | 20.76% | 20.38% | 18.32% | 19.67% |
| Research & Development | 216.58M | 221.62M | 274.97M | 205.39M | 189.34M | 194.00M | 139.40M | 124.28M | 125.93M | 121.14M | 133.02M | 132.64M | 115.82M | 95.41M | 107.25M | 108.06M | 111.62M | 99.72M | 87.37M | 87.05M | 83.15M | 86.45M | 81.32M | 86.12M | 71.20M | 46.00M | 44.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.02B | 1.03B | 1.23B | 917.89M | 815.32M | 811.91M | 616.17M | 600.89M | 598.85M | 659.34M | 585.85M | 632.73M | 628.60M | 490.66M | 504.70M | 522.88M | 444.41M | 376.85M | 365.46M | 387.54M | 386.40M | 431.30M | 411.15M | 418.98M | 327.10M | 226.30M | 243.40M | 290.90M | 284.90M | 278.20M | 234.60M | 242.00M | 223.10M | 195.90M | 179.90M | 169.30M | 151.40M | 133.20M | 130.10M |
| Other Expenses | 0.00 | 25.26M | 36.41M | -23.52M | -27.69M | -13.21M | 33.59M | -3.73M | -4.80M | -5.54M | -14.84M | -2.92M | -3.88M | -2.14M | 0.00 | 0.00 | -15.35M | 1.74M | -1.50M | 28.89M | 25.67M | 23.11M | 0.00 | 87.72M | 66.10M | 50.40M | 44.60M | 40.90M | 39.40M | 36.80M | 37.80M | 36.30M | 33.70M | 29.90M | 25.50M | 24.60M | 21.20M | 16.40M | 15.10M |
| Operating Expenses | 1.24B | 1.25B | 1.50B | 1.12B | 1.00B | 1.01B | 755.57M | 725.16M | 724.78M | 780.48M | 718.87M | 765.37M | 744.42M | 586.07M | 611.95M | 630.95M | 540.69M | 478.31M | 451.33M | 503.48M | 495.22M | 540.87M | 492.46M | 592.81M | 464.40M | 322.70M | 332.90M | 331.80M | 324.30M | 315.00M | 272.40M | 278.30M | 256.80M | 225.80M | 205.40M | 193.90M | 172.60M | 149.60M | 145.20M |
| Cost & Expenses | 2.45B | 2.57B | 3.72B | 2.80B | 2.49B | 2.44B | 1.94B | 1.83B | 1.96B | 2.01B | 1.91B | 1.92B | 1.82B | 1.53B | 1.64B | 1.74B | 1.60B | 1.40B | 1.31B | 1.51B | 1.40B | 1.44B | 1.21B | 1.51B | 1.25B | 1.31B | 1.37B | 1.34B | 1.34B | 1.27B | 2.58B | 2.67B | 2.56B | 2.37B | 1.55B | 1.31B | 1.16B | 1.08B | 1.07B |
| Interest Income | 72.13M | 3.59M | 2.24M | 1.01M | 1.50M | 1.14M | 2.57M | 702.00K | 673.00K | 667.00K | 650.00K | 747.00K | 1.88M | 832.00K | 1.04M | 4.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 98.81M | 103.96M | 102.13M | 49.71M | 63.63M | 66.98M | 43.94M | 41.53M | 38.00M | 36.27M | 49.92M | 45.79M | 24.78M | 15.89M | 17.16M | 82.14M | 41.70M | 0.00 | 0.00 | 47.71M | 105.08M | 279.72M | 128.31M | 74.63M | 7.00M | 0.00 | 64.60M | 8.90M | 0.00 | 121.80M | 12.10M | 0.00 | 900.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 431.77M | 427.00M | 311.44M | 246.51M | 214.03M | 180.59M | 105.00M | 99.97M | 121.48M | 125.26M | 154.94M | 126.87M | 129.26M | 108.96M | 113.11M | 125.10M | 103.50M | 66.84M | 124.38M | 89.51M | 89.78M | 96.11M | 84.26M | 127.26M | 66.10M | 50.40M | 44.60M | 48.20M | 36.00M | 36.80M | 30.50M | 31.10M | 29.70M | 19.90M | 15.00M | 17.70M | 12.20M | 16.40M | 15.10M |
| EBITDA | 713.56M | 1.30B | 1.73B | 1.20B | 609.55M | 518.76M | 424.63M | 405.96M | 378.63M | 322.61M | 331.73M | 223.24M | 200.06M | 267.04M | 200.91M | 262.65M | 264.89M | 219.24M | 287.59M | 266.58M | 223.51M | 156.13M | 200.13M | 311.28M | 177.50M | 82.10M | 166.20M | 135.90M | 118.70M | 168.00M | 151.30M | 154.30M | 154.90M | 127.60M | 113.40M | 115.80M | 91.50M | 57.20M | 79.00M |
| EBITDA Ratio | 25.94% | 36.19% | 34.45% | 32.00% | 20.09% | 18.13% | 20.32% | 18.21% | 18.02% | 15.02% | 17.19% | 15.25% | 11.40% | 15.41% | 14.39% | 16.42% | 15.20% | 14.24% | 24.34% | 15.80% | 17.83% | 14.58% | 21.19% | 18.36% | 17.89% | 5.83% | 11.38% | 9.52% | 8.36% | 12.61% | 5.61% | 5.53% | 5.76% | 5.16% | 6.87% | 8.23% | 7.40% | 5.00% | 6.84% |
| Operating Income | 300.56M | 742.70M | 1.33B | 978.58M | 361.97M | 323.88M | 304.80M | 283.07M | 286.13M | 210.74M | 217.44M | 195.66M | 89.70M | 153.60M | 147.61M | 192.97M | 168.17M | 153.40M | 234.29M | 177.07M | 183.91M | 123.37M | 197.58M | 184.03M | 104.40M | 31.70M | 121.60M | 87.70M | 82.70M | 131.20M | 120.80M | 123.20M | 125.20M | 107.70M | 98.40M | 98.10M | 79.30M | 40.80M | 63.90M |
| Operating Income Ratio | 10.93% | 22.43% | 26.29% | 25.87% | 12.55% | 11.66% | 13.50% | 13.38% | 12.65% | 9.42% | 10.04% | 9.25% | 4.67% | 9.01% | 8.15% | 9.96% | 9.41% | 9.92% | 15.90% | 10.49% | 11.98% | 8.20% | 14.86% | 10.86% | 7.66% | 2.25% | 8.32% | 6.14% | 5.83% | 9.85% | 4.48% | 4.42% | 4.66% | 4.35% | 5.96% | 6.98% | 6.42% | 3.56% | 5.53% |
| Total Other Income/Expenses | -117.59M | -90.86M | -54.88M | 39.09M | -124.83M | -66.20M | 1.10M | -50.51M | -42.12M | 4.60M | -53.76M | -140.50M | -26.77M | -10.78M | -15.79M | -45.61M | -16.88M | -2.67M | -74.29M | -38.33M | -56.39M | -32.87M | -163.43M | -39.54M | -66.50M | 124.30M | -35.80M | -7.30M | 3.40M | -76.90M | 1.10M | -2.10M | -4.90M | -500.00K | 1.40M | -700.00K | 1.70M | 31.50M | 24.70M |
| Income Before Tax | 182.98M | 651.84M | 1.28B | 906.36M | 237.14M | 257.68M | 296.72M | 244.07M | 244.02M | 169.60M | 153.33M | 50.59M | 62.93M | 161.98M | 130.68M | 147.36M | 151.29M | 150.74M | 66.66M | 136.75M | 80.88M | -8.55M | 34.15M | 144.49M | 44.90M | 156.00M | 54.00M | 80.40M | 86.10M | -17.10M | 121.90M | 121.10M | 120.30M | 107.20M | 99.80M | 97.40M | 81.00M | 72.30M | 88.60M |
| Income Before Tax Ratio | 6.65% | 19.68% | 25.26% | 23.96% | 8.22% | 9.28% | 13.15% | 11.54% | 10.79% | 7.58% | 7.08% | 2.39% | 3.28% | 9.50% | 7.21% | 7.61% | 8.46% | 9.75% | 4.52% | 8.10% | 5.27% | -0.57% | 2.57% | 8.52% | 3.29% | 11.08% | 3.70% | 5.63% | 6.07% | -1.28% | 4.52% | 4.34% | 4.47% | 4.33% | 6.05% | 6.93% | 6.55% | 6.31% | 7.67% |
| Income Tax Expense | 3.47M | 129.16M | 347.60M | 178.27M | 9.39M | 20.21M | 139.83M | 28.36M | 31.33M | 8.44M | -12.19M | -17.85M | 62.75M | 26.06M | 37.93M | 21.22M | 17.46M | 32.41M | 128.00K | 38.50M | 25.87M | -4.42M | 34.77M | 58.42M | 16.50M | 54.00M | 23.40M | 25.90M | 31.80M | 15.00M | 42.30M | 33.30M | 39.10M | 33.20M | 29.90M | 28.70M | 25.50M | 27.40M | 32.90M |
| Net Income | 693.09M | 569.18M | 943.16M | 727.89M | 227.56M | 237.93M | 156.89M | 234.30M | 212.43M | 157.78M | 167.21M | 69.94M | 174.00K | 135.92M | 85.60M | 126.41M | 131.69M | 119.58M | 66.53M | 96.04M | 52.96M | -4.14M | -620.00K | 90.52M | 28.40M | 102.00M | 33.70M | 60.20M | 54.30M | -32.10M | 79.60M | 87.80M | 81.20M | 74.00M | 69.90M | 68.70M | 55.50M | 44.90M | 55.70M |
| Net Income Ratio | 25.20% | 17.19% | 18.61% | 19.24% | 7.89% | 8.56% | 6.95% | 11.08% | 9.39% | 7.05% | 7.72% | 3.31% | 0.01% | 7.98% | 4.72% | 6.52% | 7.37% | 7.73% | 4.51% | 5.69% | 3.45% | -0.27% | -0.05% | 5.34% | 2.08% | 7.24% | 2.31% | 4.22% | 3.83% | -2.41% | 2.95% | 3.15% | 3.02% | 2.99% | 4.24% | 4.89% | 4.49% | 3.92% | 4.82% |
| EPS | 5.56 | 4.51 | 8.12 | 6.53 | 2.05 | 2.15 | 1.43 | 2.14 | 1.89 | 1.40 | 1.49 | 0.61 | 0.00 | 1.16 | 0.74 | 1.07 | 1.11 | 0.96 | 0.51 | 0.75 | 0.42 | -0.03 | -0.01 | 0.92 | 0.31 | 1.13 | 0.37 | 0.64 | 0.53 | -0.29 | 0.71 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| EPS Diluted | 5.55 | 4.50 | 8.08 | 6.49 | 2.04 | 2.13 | 1.42 | 2.12 | 1.87 | 1.39 | 1.47 | 0.61 | 0.00 | 1.15 | 0.73 | 1.07 | 1.09 | 0.95 | 0.51 | 0.74 | 0.41 | -0.03 | -0.01 | 0.89 | 0.31 | 1.11 | 0.37 | 0.64 | 0.51 | -0.29 | 0.71 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| Weighted Avg Shares Out | 124.70M | 126.16M | 116.17M | 111.51M | 110.83M | 110.56M | 109.86M | 109.48M | 112.51M | 112.59M | 112.25M | 113.73M | 112.98M | 117.11M | 116.25M | 117.66M | 118.64M | 124.57M | 129.52M | 128.06M | 126.09M | 125.57M | 104.56M | 98.39M | 91.30M | 90.27M | 91.08M | 94.80M | 103.03M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
| Weighted Avg Shares Out (Dil) | 124.81M | 126.43M | 116.67M | 112.09M | 111.50M | 111.53M | 110.86M | 110.31M | 113.32M | 113.74M | 113.50M | 114.86M | 113.86M | 117.98M | 116.59M | 118.69M | 120.81M | 125.88M | 131.43M | 129.79M | 129.17M | 125.57M | 107.83M | 101.71M | 91.30M | 91.89M | 91.08M | 94.80M | 105.98M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View
Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.
Revvity tumbles on 3Q earnings miss; revised guidance in “increasingly challenging” environment
Revvity Inc posted third-quarter revenue and earnings that fell short of market expectations and lowered its full-year guidance in what it described as an increasingly challenging end-market environment. The life sciences and diagnostics business reported a 5.8% decline in revenue...
Revvity Stock Tumbles 18% as Demand From Pharma and Biotech Customers Falls
Revvity posts third-quarter earnings of $1.18 a share, 1 cent below estimates. Revenue of $670.7 million also came in below forecasts.
Compared to Estimates, Revvity (RVTY) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revvity's stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlook
Shares of Revvity Inc. RVTY, -1.09% tumbled 14.2% toward a 3 1/2-year low Monday, enough to pace the S&P 500's SPX, +0.72% premarket decliners, after the health sciences company missed third-quarter earnings expectations and cut its full-year outlook citing “increased...
Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.51 per share a year ago.
Revvity cuts annual forecast on weak demand for diagnostics, contract research
Revvity Inc cut its full-year sales and revenue forecasts after missing Wall Street estimates for third-quarter results, hurt by weak demand for its supplies to life science researchers and diagnostic solutions.
Revvity Announces Financial Results for the Third Quarter of 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 1, 2023. The Company reported GAAP earnings per share of $0.08, as compared to $0.67 in the same period a year ago. GAAP revenue...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 9, 2024 to all shareholders of record at the close of...
Revvity Debuts Inaugural ESG Report
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its inaugural 2023 Environmental, Social and Governance (ESG) Report. An in-depth overview of the Company's ESG strategy, initiatives and performance, the report showcases the Company's deepening commitment to driving more sustainable solutions,...
Source: https://incomestatements.info
Category: Stock Reports